<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03034018</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002667</org_study_id>
    <nct_id>NCT03034018</nct_id>
  </id_info>
  <brief_title>Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Determine the Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia in Midlife Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effect of suvorexant on insomnia symptoms in peri-
      and postmenopausal women who are experiencing sleep difficulties related to nighttime hot
      flashes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2017</start_date>
  <completion_date type="Actual">April 3, 2020</completion_date>
  <primary_completion_date type="Actual">April 3, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ISI score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in Insomnia Severity Index (ISI) score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>suvorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>suvorexant 10-20 mg taken at bedtime for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo taken at bedtime for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suvorexant</intervention_name>
    <description>10-20 mg taken at bedtime for four weeks</description>
    <arm_group_label>suvorexant</arm_group_label>
    <other_name>Belsomra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo taken at bedtime for four weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Peri- or postmenopausal women

          -  DSM-5 criteria for Insomnia disorder, with onset of symptoms attributed to hot flashes

          -  Some awakenings co-occur with a hot flash

          -  Score on the Insomnia Severity Index (ISI) measure â‰¥15

          -  Hot flashes present, including at night

        Exclusion Criteria:

          -  Diagnosis of other primary sleep disorders

          -  Shift workers

          -  Current or expected use of hypnotic medications

          -  Current major depressive episode

          -  Lifetime history of bipolar disorder, psychosis, or other serious mental health
             problem

          -  Current alcohol/substance use disorder

          -  Obesity

          -  Renal or hepatic disease

          -  Pregnancy or breastfeeding

          -  Recent malignancy

          -  Recent surgery

          -  Neurological disorder or cardiovascular disease raising safety concerns

          -  Medical instability considered to interfere with study procedures

          -  Concomitant medications with drug interaction or co-administration concerns

          -  Contraindications or allergic responses to suvorexant

          -  Recent or planned travel across time zones

          -  Excessive coffee or cigarette use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadine Joffe, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Hadine Joffe, MD MSc</investigator_full_name>
    <investigator_title>Executive Director, Connors Center for Women's Health and Gender Biology</investigator_title>
  </responsible_party>
  <keyword>insomnia</keyword>
  <keyword>hot flashes</keyword>
  <keyword>menopause</keyword>
  <keyword>suvorexant</keyword>
  <keyword>belsomra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

